Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the official launch of the Myomo Academy, a comprehensive learning management system for professionals in Orthotics & Prosthetics (O&P) and Rehabilitation.

The Myomo Academy is being launched during the 2024 AOPA (American Orthotic and Prosthetic Association) National Assembly, which is underway in Charlotte, NC until September 15, 2024. Attendees are invited to visit Myomo at booth #401 to gain first-hand insights into the new educational platform and receive access credentials.

The Myomo Academy is designed to provide ongoing education, featuring a wide range of courses from introductory to advanced levels. With a structured curriculum tailored to support Centers of Excellence and therapy training, these courses will offer easy access to clinically relevant content and ensure that clinicians remain at the forefront of upper-extremity myoelectric orthosis technology.

“We are thrilled to introduce the Myomo Academy as a central resource for enhancing outcomes and education in O&P and rehabilitation, and we’re excited to help more clinicians advance their knowledge of myoelectric orthotics,” said Kathy Sawyers, PT, ATP, Sr. Director of Clinical Outcomes.

“By leveraging our expertise, we are committed to delivering exceptional educational content that is unique and not readily available elsewhere, helping clinicians provide the best care for their patients,” said Paul R. Gudonis, Chairman and CEO of Myomo, Inc.

About Myomo, Inc.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care.

Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit www.myomo.com.